Valeant Pharmaceuticals Intl Inc (NYSE: VRX) investors were disappointed to see that popular vocal activist investor Bill Ackman finally abandoned his stake in Valeant for what was likely nearly a

Valeant Pharmaceuticals Intl Inc (NYSE: VRX)'s refinancing announcement on Tuesday shouldn't be celebrated by investors, at least according to Gadfly's Max Nisen.

Billionaire investor Bill Ackman cut his losses in Valeant Pharmaceuticals Intl Inc (NYSE: VRX)'s stock so now is the time for both the company and hedge fund manager to move on.

Forbes released its ranking of the world's richest people. Ironic or not, just one billionaire in the top 10 earned their fortune through investments and banking: Warren Buffett.

Valeant Pharmaceuticals Intl Inc (NYSE: VRX) plummeted 11 percent Tuesday after notable hedge fund manager Bill Ackman exited his large position of the pharmaceutical company at a loss that could be in the billions of dollars.

After a headline-filled tenure, Bill Ackman's investment in Valeant Pharmaceuticals Intl Inc (NYSE: VRX) is over.

Valeant Pharmaceuticals Intl Inc (NYSE: VRX) fell to a new 52-week low of $10.50 after Bill Ackman sold his stake.

One of the worst chapters of Bill Ackman’s investing career is officially over.

Herbalife Ltd. (NYSE: HLF) shares are up 2.3 percent Monday after Carl Icahn put to rest any speculation that he may be worried about his Herbalife investment ahead of the upcoming release of the “Betting On Zero” documentary.

Back in January, Benzinga published a series of articles where Don Steinbrugge, one of the top experts in the hedge fund industry, shared a preview of the top trends he expects to see among hedge funds in 2017.

QTR Research is the latest firm to weigh in on controversial multi-level marketing nutrition company Herbalife Ltd.

Billionaire investor Carl Icahn's Icahn Enterprises LP (NASDAQ: IEP) announced last Wednesday the hiring of pharma academician Richard Mulligan as a portfolio manager. The announcement has set tongues wagging about Carl Icahn's renewed interest in the pharma/biotech sector.

Astute investors who have mastered the art and science of investing are an elite group to whom an average investor looks up to for portfolio modeling. Given the fickleness associated with the stock market, it's a tough proposition to continuously make money.

Billionaire investor and corporate raider Carl Icahn has trained his eyes on Bristol-Myers Squibb Co (NYSE: BMY).

Notable activist investor Carl Icahn helped boost shares of Bristol-Myers Squibb Co (NYSE: BMY) on Wednesday after his name was attached to the stock. This comes just a few days after Nelson Pelt

Bristol-Myers Squibb Co (NYSE: BMY) shares spiked 4.5 percent Tuesday on news that Carl Icahn bought a stake in the company.

Shares of Hertz Global Holdings, Inc (NYSE: HTZ) were trading lower by nearly 4 percent early Friday morning after analysts at Credit Suisse downgraded the stock to Underperform from Neutral with a price target lowered to $15 from a previous $27.

Valeant Pharmaceuticals Intl Inc (NYSE: VRX) shares are trading higher by $0.80 (4.8 percent) at $16.78 in Wednesday's session.

Following Nelson Peltz's Trian picking up a $3.5 billion stake in Procter & Gamble Co (NYSE: PG), Deutsche Bank looked at what the activist investor could do with the consumer products company.

Plenty of investors follow the smart money during 13-F filing season. If the managers running billion-dollar hedge funds are all buying or selling the same stock, it may serve as a strong indication that retail investors should be doing the same.

There are about 15,000 hedge funds out there, and both their fees and returns are very varied. But, what determines those factors?

Quite often, our readers ask how to invest in hedge funds: “I don’t know the first thing about them. Other than Warren Buffett, who’s good? Are the fees worth it?”

Don Steinbrugge is one of the best-known experts in the hedge fund industry, with over three decades of experience in the arena. He has been running Agecroft Partners, a global, award-winning hedge fund consulting and marketing firm for almost 10 years now.

Despite wanting to forget 2016 altogether, Pershing Square Capital investors got one last reminder of their brutal year this week when Bill Ackman’s firm sent out its annual shareholder update.

Pershing Square and Herbalife Ltd. (NYSE: HLF) have a long-standing rivalry, with the Bill Ackman-led hedge fund betting on a fall in the company's share price since May 2012.

In recent years, struggling companies have turned more and more to outsiders when looking for a direction change at the CEO position. These companies are hoping the past leadership success will translate to the struggling company as well.

In what should come as no surprise to any American, newly elected President Donald Trump’s special advisor on regulatory reform and long-time Trump supporter Carl Icahn has tweeted that he loved Trump’s inauguration speech.

Following reports of Hunter Harrison attempting a management shakeup at CSX Corporation (NASDAQ: CSX) along with hedge fund manager and activist investor Paul Hilal, Loop Capital's Rick Paterson told Benzinga that it isn't